Dencatistat is an investigational new drug that is being evaluated by Step Pharma for the treatment of essential thrombocythemia, B-cell lymphoma, and T-cell lymphoma. It is a CTPS1 enzyme inhibitor.
Clinical trials
Dencatistat is currently under clinical trials for lymphomas, solid tumors, and essential thrombocythemia.
References